Title : Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.

Pub. Date : 2022 May

PMID : 35493119






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ibrutinib, a once-daily Bruton tyrosine kinase inhibitor, may mitigate COVID-19-induced lung damage by reducing inflammatory cytokines. ibrutinib Bruton tyrosine kinase Homo sapiens